The purpose of our review is to bring a better and updated understanding towards the activated pathological mechanisms in IBD patients during nutrition, novel pharmacotherapy (vedolizumab, ustekinumab, anti-IL23 p19 drugs), and vaccination. The gene discussed is IL23A; the disease is inflammatory bowel disease.